It is with great excitement that we unveil our network-wide redesign. Please read further to learn more about a few of our new features, and browse around to explore the new site!
Patients with heart failure and reduced ejection fraction (HF-REF) treated with an investigational angiotensin receptor neprilysin Inhibitor (ARNI) are more likely to reduce cardiovascular death and heart failure hospitalization than...
Teens who received the collaborative care intervention in primary care had significantly greater improvements in depressive symptoms than teens who were receiving treatment as usual.

LATEST
FDA: Limit use of anticoagulant edoxaban

FDA advisors have recommended approval of a 60-mg dose of edoxaban (Daiichi Sankyo), a once-daily anticoagulant that ...

Ibuprofen safe, effective in ...
[BLOG]: How to position your ...
[BLOG]: Emerging targets in ...
Ebola clinical activity heats up ...

FDA APPROVALS
FDA approves combo pill for adults ...

FDA has approved once-daily dapagliflozin and metformin hydrochloride extended-release (Xigduo, AstraZeneca) (XR) for the ...

FDA approves first vaccine for ...
New antiarrhythmic agent gets FDA ...
FDA approves Obizur for acquired ...

CLINICAL
FDA approves combo pill for adults ...

FDA has approved once-daily dapagliflozin and metformin hydrochloride extended-release (Xigduo, AstraZeneca) (XR) for the ...

FDA: Limit use of anticoagulant edoxaban
FDA approves first vaccine for ...
Ibuprofen safe, effective in ...

DRUGS IN PERSPECTIVE
Drug Overview: Zykadia (ceritinib)

Zykadia (ceritinib) is a tyrosine kinase inhibitor that was approved by FDA on April 29, 2014, as a medication for the ...

Drugs in Perspective: Dalvance
Drug Overview: Tasimelteon (Hetlioz)
Drug Overview: Aptiom ...

Latest Tweets Follow